Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-65

First 65 Last

Share
Profile

Follow
Jdmoney

1,966 Posts.

328

24/06/22

14:36

Post #: 62188868
Share

Originally posted by Phantom1: ↑

(Posted more for Mason and Wombat to chew over and consider as they seem to collate all the interesting work)

If RAC wants to use Zantrene as a CPI enhancer rather than a chemotherapy agent (effectively giving a patient 2 CPI's) they still need to partner with a T-cell therapy company as the results in this study are not good enough and have been well overtaken by CPI plus oncolytic viral approaches. The COH paper used activated T-cells and Zantrene (without anti- PD-1) to get the excellent responses they published. I have been waiting for the penny to drop with management (or at least for them to publically acknowledge the point). Simply put, the immune activation (rather than the CPI effect) seen from Zantrene is not sufficient to avoid another combinatorial approach. Lots to choose from.
The next set of pre-clin could compare PD-1 to Zantrene with and without a t-cell approach and see what is what.
Interestingly the COH paper showed that Zantrene acted as a CTLA inhibitor (as against PD-1).
The renal cell data released a few weeks ago was also interesting but I noted that the concentration to kill some of the cancer cell lines was very similar to that which also killed the normal kidney cell line.

Expand

Thanks Phantom1. What have you used as your comparator for this for reference?

RAC Price at posting: $1.80 Sentiment: None Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

AZL

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

IVZ

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

PAM

PAM secures high-grade Chilean copper play in strong territory

There are more pages in this discussion • 27 more messages in this thread...

First 65 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.61		Change 0.000(0.00%)		Mkt cap ! $273.4M

Open	High	Low	Value	Volume
$1.61	$1.66	$1.60	$207.2K	127.1K

Buyers (Bids)

No.	Vol.	Price($)
6	25510	$1.60

Sellers (Offers)

Price($)	Vol.	No.
$1.64	12000	1

View Market Depth

No.	Vol.	Price($)
6	25510	1.600
1	31000	1.590
1	10000	1.585
2	8233	1.560
4	15571	1.550

Price($)	Vol.	No.
1.640	12000	1
1.655	858	1
1.665	352	1
1.670	1845	1
1.690	1085	2

Last trade - 15.49pm 29/07/2024 (20 minute delay)

RAC (ASX) Chart

Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-65

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

PAM secures high-grade Chilean copper play in strong territory

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-65

Top Stories

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

PAM secures high-grade Chilean copper play in strong territory

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News